How do you approach RA management in a patient who develops a new solid tumor while on therapy?

Risk-benefit ratios need to be individually assessed. There are several aspects to take into account:

1. Choice of DMARD - Data on impact of various DMARDS on cancer recurrence or progression is scarce, especially for patients with active cancer. In general, there are few concerns for conventional DMA...

This is a very difficult question to answer- but working carefully with the oncologist, in conjunction with the patient is critical. Some solid tumors require resection, some radiation, some conventional chemotherapy or targeted therapy and most will likely require a combination. If the patient is o...